SCTX — Scribe Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1853921 ·
Last close
$15.77
Market Cap
$298.64M
52W High
$39.60
52W Low
$13.50
ADV30
365,516
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,918,000 | — | -9,395,000 | -6,477,000 | 57,927,000 | 35,586,000 | 222,773,000 |
| Mar 2026 | 2,233,000 | — | -12,427,000 | -17,347,000 | 65,208,000 | 20,381,000 | 223,946,000 |
| Jun 2025 | 4,898,000 | — | -11,627,000 | -9,903,000 | — | — | — |
| Mar 2025 | 17,125,000 | — | -5,557,000 | -3,425,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,144,000
Investing CF
$61,049,000
Financing CF
$-1,737,000
CapEx
$-957,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-181,531,000
Inventory
—
Receivables
$1,231,000
ST Investments
$7,423,000
EBIT TTM
$-35,669,000
Pretax Income TTM
$-37,739,000
Interest Exp TTM
$2,070,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$14,825,000
EBITDA
$-40,925,000
Free Cash Flow
—
Enterprise Value
$140,728,816
Total Cash
$174,230,000
Total Debt
$5,141,000
Shares Out
18,937,519
Trailing EPS
$-3.84
Book Value
$6.61
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,174,000 | -26,070,000 | -21,808,000 | 78,219,000 | 221,638,000 | -143,419,000 | -45,213,000 |
| Dec 2024 | 27,413,000 | -42,829,000 | -47,786,000 | 127,971,000 | 253,830,000 | -125,859,000 | -45,235,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$57,927,000
Forward EPS
$-3.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | $297.14M | $4.70 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
| XFOR | X4 Pharmaceuticals, Inc | $315.53M | $3.09 | — |
| EDIT | Editas Medicine, Inc. | $281.67M | $1.83 | — |
News headlines (Yahoo Finance, 1h cache)
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
2026-11-18 13:00 · Yahoo
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-12 21:05 · Yahoo
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
2026-11-05 13:00 · Yahoo
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
2026-11-04 13:00 · Yahoo
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-22 11:10 · Yahoo
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
2026-09-17 20:09 · Yahoo
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-09-02 20:05 · Yahoo
Scribe Therapeutics to Participate in Upcoming Investor Conferences
2026-09-01 12:00 · Yahoo
Why Is Sanofi (ENXTPA:SAN) Expanding Its R And D Bets In Vaccines And Gene Editing?
2026-11-13 06:15 · Yahoo
Cathie Wood Makes $64 Million Bet on Two Stocks
2026-09-28 19:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.